Momentum Test: Can Ingrevia Keep the Q1 Pace?
After a blowout Q1 FY27—revenue +25%, EBITDA +36%, PAT +41% YoY—the Street is primed for a sustained run. But valuation skepticism and macro headwinds linger. What continuity looks like, and where the Street sees cracks.
What to Expect
After a stellar Q1 FY27, the bar is high. Revenue growth in the 22–28% range YoY (tracking ₹1,350–1,400 Cr) would be consistent with CDMO momentum and full-year guidance, while EBITDA margins at 15.5–16% would suggest pricing power holding up despite cost inflation. PAT growth in the 30–40% range would signal operational leverage intact. A downside miss—revenue growth 50bps, PAT growth <25%—would test whether Q1 was a one-off or the new normal.
~₹1,350–1,400 Cr
25% YoY growth trajectory; Q1 baseline ₹1,300 Cr
~15.5–16%
Q1 was 15.8%; track pricing vs cost pressures
~30–40% YoY
Operating leverage; tax/finance normalization
On Track?
Q1 FY27 was a breakout—25% revenue, 36% EBITDA, 41% PAT growth YoY suggest the CDMO cycle is firing on all cylinders and the company is gaining share in specialty chemicals. Full-year FY27 guidance, if sustained at this pace, points to revenues in the ₹5,400–5,600 Cr range and mid-16% EBITDA margins. Q2 continuity—no reversal of client orders, no margin slip—would validate the run-rate and signal FY27 is a stepping-stone, not a peak.
What the Street Says
Since Last Quarter: Filings & Events
1 · Electronics Subsidiary (Oct 13, Oct 1)
Jubilant Ingrevia incorporated Jubilant Advanced Electronics Limited as a wholly owned subsidiary to enter Electronics Development and Manufacturing Services (EDMS). Strategic play into adjacent services; watch for capex, revenue ramp timelines, and competitive positioning.
2 · Zettaone Acquisition (Aug 18)
Binding term sheet to acquire 40% stake in Zettaone Technologies for ₹189.2 Cr. Aligns with electronics/next-gen capability building. Watch for deal closure timing, integration progress, and any capital calls.
3 · Senior Supply Chain Exec Exit (Oct 1)
Sr. VP Supply Chain, Birajeev Singh, resigns effective Nov 5. Routine turnover or signal of operational stress? Monitor for any guidance commentary on supply-chain resilience.
4 · Commercial Paper Issuance (Sep 24)
₹100 Cr CP issued on Sep 24 at 90-day tenor (maturity Dec 23). Liquidity management; routine for capex-heavy cycles. Low signal unless accompanied by drawdown of credit facilities.
5 · Dividend KYC Withholding (Oct 14)
Final dividend for FY26 withheld for select shareholders due to KYC non-compliance. Routine administrative; no operational impact.
Valuation & Price Setup
Stock at ₹604 is 31.75% off ATH (₹885), though +12.41% off the 52-week low (₹537.3). Technicals: RSI 39 (neutral), trading below SMA20 (₹632), SMA50 (₹662), and SMA200 (₹663.5)—a bearish setup despite fundamental momentum. Analyst consensus of ₹967 implies 60%+ upside; risk-reward lopsided if Q2 sustains the Q1 run-rate. Watch price action on result day—breadth breakout (volume, sector rotation) vs profit-taking on any miss.
The Setup
Jubilant Ingrevia enters Q2 FY27 print as a story of execution resuming: a CDMO cycle firing, a diversification bet (electronics) in motion, and analyst consensus firmly bullish. The Street expects 22–28% revenue growth, stable-to-rising margins, and 30%+ PAT growth. Price action—down from all-time highs but fundamentals strong—sets up a momentum test: does the company sustain Q1's trajectory, or does the print reveal cracks in capacity, pricing, or pipeline? Watch revenue growth rate (is it accelerating or settling?), EBITDA margin (pricing vs cost), and any commentary on CDMO order book and Zettaone/electronics timeline.
Three things to watch on result day:
1. Growth momentum: Does revenue growth hold 25%+ YoY, or does it slip to 20%? That signals CDMO demand durability.
2. Margin resilience: EBITDA margin at 15.5%+ keeps the runway. A 50bps+ slip invites valuation debate.
3. FY27 guidance refresh: Watch for updated full-year commentary—if the company raises, the Street's ₹967 target is conservative; if guidance is capped, consensus may need revision.
Informational and educational content only. Not investment advice.